
Everest Medicines Announces NMPA Full Approval Of NEFECON® For The Treatment Of Primary Immunoglobulin A Nephropathy (...
(MENAFN- EQS Group) Shanghai, China – May 7, 2025 – Everest Medicines (HKEX 1952,“Everest”, or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative …